Combating COVID-19 with mesenchymal stem cell therapy | Zendy

Keshav Rajarshi | Zendy; Aroni Chatterjee | Zendy; Shashikant Ray | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Combating COVID-19 with mesenchymal stem cell therapy

Author(s) -

Keshav Rajarshi,

Aroni Chatterjee,

Shashikant Ray

Publication year - 2020

Publication title -

biotechnology reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.932

H-Index - 36

ISSN - 2215-017X

DOI - 10.1016/j.btre.2020.e00467

Subject(s) - mesenchymal stem cell , immune system , chemokine , internalization , cytokine storm , virus , immunology , stem cell , cell , biology , inflammation , proinflammatory cytokine , medicine , covid-19 , disease , microbiology and biotechnology , infectious disease (medical specialty) , pathology , genetics

The COVID-19 disease is caused by a positive stranded RNA virus called SARS-CoV-2. The virus mainly targets the pulmonary epithelial cells as it's initial site of infection by letting its surface spike protein interact and bind to the host ACE2 receptor. The internalization and gradual replication of the virus results in an exaggerated immune response triggering release of many pro-inflammatory cytokines and chemokines. This immune storm is responsible for multiple health hazards in the host ultimately leading to multiple organ failure. Mesenchymal stem cell therapy offers a promising approach towards mitigating the delirious effects of the infection in the COVID-19 patients. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. This review has been organized to put forward the positive aruments and implications in support of mesenchymal stem cell therapy as a necessary approach for treating COVID-19 patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research